OTCMKTS:ISCO

International Stem Cell Competitors

$0.54
-0.06 (-10.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.54
Now: $0.54
$0.60
50-Day Range
$0.60
MA: $0.78
$0.96
52-Week Range
$0.27
Now: $0.54
$1.08
Volume17,238 shs
Average Volume8,284 shs
Market Capitalization$4.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.03

Competitors

International Stem Cell (OTCMKTS:ISCO) Vs. NMUS, NVUS, NVLNF, NTEC, NRIFF, and MCUJF

Should you be buying ISCO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to International Stem Cell, including Nemus Bioscience (NMUS), Novus Therapeutics (NVUS), Novelion Therapeutics (NVLNF), Intec Pharma (NTEC), Nuvo Pharmaceuticals (NRIFF), and Medicure (MCUJF).

Nemus Bioscience (OTCMKTS:NMUS) and International Stem Cell (OTCMKTS:ISCO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Valuation and Earnings

This table compares Nemus Bioscience and International Stem Cell's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nemus BioscienceN/AN/A$-19,190,000.00N/AN/A
International Stem Cell$9.47 million0.43$-4,260,000.00N/AN/A

International Stem Cell has higher revenue and earnings than Nemus Bioscience.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Nemus Bioscience and International Stem Cell, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nemus Bioscience0000N/A
International Stem Cell0000N/A

Risk and Volatility

Nemus Bioscience has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, International Stem Cell has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.

Profitability

This table compares Nemus Bioscience and International Stem Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nemus BioscienceN/AN/A-924.42%
International Stem Cell-55.56%N/A-72.21%

Summary

International Stem Cell beats Nemus Bioscience on 4 of the 5 factors compared between the two stocks.

International Stem Cell (OTCMKTS:ISCO) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for International Stem Cell and Novus Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
International Stem Cell0000N/A
Novus Therapeutics01102.50

Novus Therapeutics has a consensus target price of $50.75, suggesting a potential upside of 371.22%. Given Novus Therapeutics' higher possible upside, analysts plainly believe Novus Therapeutics is more favorable than International Stem Cell.

Profitability

This table compares International Stem Cell and Novus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
International Stem Cell-55.56%N/A-72.21%
Novus TherapeuticsN/A-133.49%-30.52%

Earnings and Valuation

This table compares International Stem Cell and Novus Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Stem Cell$9.47 million0.43$-4,260,000.00N/AN/A
Novus TherapeuticsN/AN/A$-16,010,000.00($21.58)-0.50

International Stem Cell has higher revenue and earnings than Novus Therapeutics.

Risk and Volatility

International Stem Cell has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

Summary

Novus Therapeutics beats International Stem Cell on 5 of the 8 factors compared between the two stocks.

International Stem Cell (OTCMKTS:ISCO) and Novelion Therapeutics (OTCMKTS:NVLNF) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Insider and Institutional Ownership

48.6% of Novelion Therapeutics shares are held by institutional investors. 81.7% of International Stem Cell shares are held by company insiders. Comparatively, 3.6% of Novelion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for International Stem Cell and Novelion Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
International Stem Cell0000N/A
Novelion Therapeutics0000N/A

Profitability

This table compares International Stem Cell and Novelion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
International Stem Cell-55.56%N/A-72.21%
Novelion TherapeuticsN/AN/AN/A

Risk & Volatility

International Stem Cell has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Novelion Therapeutics has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500.

Earnings and Valuation

This table compares International Stem Cell and Novelion Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Stem Cell$9.47 million0.43$-4,260,000.00N/AN/A
Novelion Therapeutics$130.43 million0.11$-108,330,000.00N/AN/A

International Stem Cell has higher earnings, but lower revenue than Novelion Therapeutics.

Summary

Novelion Therapeutics beats International Stem Cell on 5 of the 8 factors compared between the two stocks.

International Stem Cell (OTCMKTS:ISCO) and Intec Pharma (NASDAQ:NTEC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings for International Stem Cell and Intec Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
International Stem Cell0000N/A
Intec Pharma03102.25

Intec Pharma has a consensus target price of $13.00, suggesting a potential upside of 239.43%. Given Intec Pharma's higher possible upside, analysts clearly believe Intec Pharma is more favorable than International Stem Cell.

Profitability

This table compares International Stem Cell and Intec Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
International Stem Cell-55.56%N/A-72.21%
Intec PharmaN/A-93.54%-63.98%

Valuation and Earnings

This table compares International Stem Cell and Intec Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Stem Cell$9.47 million0.43$-4,260,000.00N/AN/A
Intec PharmaN/AN/A$-47,600,000.00($21.80)-0.18

International Stem Cell has higher revenue and earnings than Intec Pharma.

Summary

Intec Pharma beats International Stem Cell on 4 of the 7 factors compared between the two stocks.

Nuvo Pharmaceuticals (OTCMKTS:NRIFF) and International Stem Cell (OTCMKTS:ISCO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Risk & Volatility

Nuvo Pharmaceuticals has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, International Stem Cell has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.

Earnings and Valuation

This table compares Nuvo Pharmaceuticals and International Stem Cell's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals$52.41 million0.26$2.53 millionN/AN/A
International Stem Cell$9.47 million0.43$-4,260,000.00N/AN/A

Nuvo Pharmaceuticals has higher revenue and earnings than International Stem Cell.

Profitability

This table compares Nuvo Pharmaceuticals and International Stem Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals-2.81%8.02%1.11%
International Stem Cell-55.56%N/A-72.21%

Analyst Ratings

This is a breakdown of current ratings and target prices for Nuvo Pharmaceuticals and International Stem Cell, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals0000N/A
International Stem Cell0000N/A

Summary

Nuvo Pharmaceuticals beats International Stem Cell on 6 of the 7 factors compared between the two stocks.

International Stem Cell (OTCMKTS:ISCO) and Medicure (OTCMKTS:MCUJF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk and Volatility

International Stem Cell has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Medicure has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for International Stem Cell and Medicure, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
International Stem Cell0000N/A
Medicure0000N/A

Valuation and Earnings

This table compares International Stem Cell and Medicure's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Stem Cell$9.47 million0.43$-4,260,000.00N/AN/A
Medicure$15.20 million0.90$-14,910,000.00N/AN/A

International Stem Cell has higher earnings, but lower revenue than Medicure.

Profitability

This table compares International Stem Cell and Medicure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
International Stem Cell-55.56%N/A-72.21%
Medicure-179.92%-63.27%-41.85%

Summary

International Stem Cell beats Medicure on 4 of the 7 factors compared between the two stocks.


International Stem Cell Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NMUS
Nemus Bioscience
0.6$0.12-0.0%$16.07 millionN/A0.00High Trading Volume
Novus Therapeutics logo
NVUS
Novus Therapeutics
1.4$10.77-5.1%$15.47 millionN/A-0.48Gap Down
NVLNF
Novelion Therapeutics
0.6$0.70-1.2%$13.77 million$130.43 million0.00Gap Down
Intec Pharma logo
NTEC
Intec Pharma
1.4$3.83-3.4%$13.76 millionN/A-0.54Gap Down
NRIFF
Nuvo Pharmaceuticals
0.7$1.20-0.0%$13.68 million$52.41 million30.00
Medicure logo
MCUJF
Medicure
0.6$1.33-3.0%$13.63 million$15.20 million-1.06
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.05-0.0%$12.67 million$7.38 million0.00Gap Up
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.24-0.0%$12.01 millionN/A-0.47Decrease in Short Interest
News Coverage
Gap Up
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.24-0.0%$12.01 millionN/A-0.47Decrease in Short Interest
News Coverage
Gap Up
iCo Therapeutics logo
ICOTF
iCo Therapeutics
0.5$0.08-0.0%$11.99 millionN/A-3.90Decrease in Short Interest
News Coverage
Teligent logo
TLGT
Teligent
1.2$0.53-7.6%$11.46 million$65.90 million-0.06News Coverage
Gap Up
BetterLife Pharma logo
BETRF
BetterLife Pharma
0.0$0.65-1.5%$11.27 millionN/A-0.87
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.12-8.4%$11.07 million$4.08 million-1.32Increase in Short Interest
News Coverage
Gap Down
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.13-0.0%$10.19 millionN/A0.00
Williston logo
WHCA
Williston
0.0$0.70-0.0%$9.51 millionN/A0.00
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.42-7.1%$9.28 million$2.66 million-14.00Gap Up
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.15-12.9%$8.64 millionN/A0.00Gap Up
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.48-4.7%$8.51 millionN/A0.00Gap Up
ULUR
ULURU
0.3$0.28-0.0%$8.17 millionN/A0.00
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36-0.0%$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08-0.0%$7.15 millionN/A0.00
KAYS
Kaya
0.7$0.44-0.0%$6.38 million$1.01 million0.00
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.05-0.0%$5.71 million$30,000.000.00High Trading Volume
Gap Down
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.20-0.0%$4.81 million$3.48 million-1.69Gap Down
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01News Coverage
FutureWorld logo
FWDG
FutureWorld
0.5$0.00-0.0%$4.56 millionN/A0.00Gap Up
Amarantus BioScience logo
AMBS
Amarantus BioScience
0.0$0.01-0.0%$3.87 millionN/A0.00Increase in Short Interest
News Coverage
Gap Down
AKRXQ
Akorn
0.1$0.03-0.0%$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01-0.0%$3.50 millionN/A0.00Gap Up
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.09-0.0%$3.50 million$3.65 million0.00News Coverage
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14-7.3%$2.88 millionN/A0.00Gap Up
RespireRx Pharmaceuticals logo
RSPI
RespireRx Pharmaceuticals
0.5$0.04-0.0%$2.82 millionN/A-0.09
VVUSQ
VIVUS
0.6$0.12-0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48-6.2%$2.02 millionN/A0.00
NSPX
Inspyr Therapeutics
0.5$0.01-0.0%$1.97 millionN/A0.00Gap Down
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01-0.0%$1.95 million$2 million0.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04-0.0%$1.78 million$530,000.000.00Gap Up
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.48-6.2%$1.70 millionN/A0.00
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.01-0.0%$1.65 million$20,000.00-0.74Gap Down
Cardax logo
CDXI
Cardax
0.0$2.00-0.0%$1.59 million$710,000.000.00News Coverage
MLNTQ
Melinta Therapeutics
0.2$0.11-0.0%$1.51 million$96.43 million0.00
WWHC
W World
0.8$4.50-35.3%$1.33 millionN/A0.00Increase in Short Interest
Gap Up
Achaogen logo
AKAOQ
Achaogen
0.6$0.03-0.0%$1.29 million$8.73 million0.00Gap Up
HSTC
HST Global
0.8$0.24-67.9%$1.24 millionN/A0.00
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.22-9.3%$1.14 millionN/A0.00Decrease in Short Interest
News Coverage
Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05-0.0%$1.12 millionN/A-0.57Upcoming Earnings
AOXG
Aoxing Pharmaceutical
0.5$0.01-0.0%$991,000.00N/A0.00Gap Up
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04-0.0%$978,000.00N/A0.00Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07-0.0%$970,000.00N/A0.00Increase in Short Interest
Gap Up
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.